Nuclear receptor isoform specificities of retinoid analogues and their effects on FR-β expression
| Agonist (specificity) . | Antagonist (specificity) . | FR-β expression . |
|---|---|---|
| ATRA (pan-RAR) | — | Increase |
| TTNPB (pan-RAR) | — | Increase |
| 9-cis RA (pan-RXR, pan-RAR) | — | Increase |
| CD336 (RARα) | — | Increase |
| CD417 (RARβ) | — | No change |
| CD2314 (RARβ) | — | No change |
| LG101093 (RAR β and RARγ) | — | Increase |
| CD2781 (RARγ) | — | Increase |
| LG100364 (pan-RXR) | — | No change |
| ATRA (pan-RAR) | LG100629 (RARα) | Decrease |
| ATRA (pan-RAR) | CD2503 (RARα) | Decrease |
| ATRA (pan-RAR) | CD2665 (RARβ, RARγ) | Decrease |
| CD336 (RARα) | LG100629 (RARα) | Decrease |
| CD336 (RARα) | CD2503 (RARα) | Decrease |
| CD336 (RARα) | CD2665 (RARβ, RARγ) | Decrease |
| LG101093 (RARβ and RARγ) | LG100629 (RARα) | Decrease |
| LG101093 (RARβ and RARγ) | CD2503 (RARα) | Decrease |
| LG101093 (RARβ and RARγ) | CD2665 (RARβ, RARγ) | Decrease |
| Agonist (specificity) . | Antagonist (specificity) . | FR-β expression . |
|---|---|---|
| ATRA (pan-RAR) | — | Increase |
| TTNPB (pan-RAR) | — | Increase |
| 9-cis RA (pan-RXR, pan-RAR) | — | Increase |
| CD336 (RARα) | — | Increase |
| CD417 (RARβ) | — | No change |
| CD2314 (RARβ) | — | No change |
| LG101093 (RAR β and RARγ) | — | Increase |
| CD2781 (RARγ) | — | Increase |
| LG100364 (pan-RXR) | — | No change |
| ATRA (pan-RAR) | LG100629 (RARα) | Decrease |
| ATRA (pan-RAR) | CD2503 (RARα) | Decrease |
| ATRA (pan-RAR) | CD2665 (RARβ, RARγ) | Decrease |
| CD336 (RARα) | LG100629 (RARα) | Decrease |
| CD336 (RARα) | CD2503 (RARα) | Decrease |
| CD336 (RARα) | CD2665 (RARβ, RARγ) | Decrease |
| LG101093 (RARβ and RARγ) | LG100629 (RARα) | Decrease |
| LG101093 (RARβ and RARγ) | CD2503 (RARα) | Decrease |
| LG101093 (RARβ and RARγ) | CD2665 (RARβ, RARγ) | Decrease |
RAR indicates retinoid acid receptor; 9-cis RA, 9-cis retinoic acid; and RXR, retinoid X receptors. See Tables 1 and 2 for other abbreviations.